For a patient with obesity in the United States, the path to a GLP-1 prescription has historically run through a primary care visit, a specialist referral, a prior authorization fight, and a pharmacy that may or may not have the drug in stock. Ro, the New York direct-to-patient telehealth company founded in 2017, is trying to compress that journey into a phone screen and a monthly fee. As of March 2026, the company says patients can save up to $1,200 per year on the Wegovy pen or $600 per year on the Wegovy pill through a collaboration with Novo Nordisk, with prepaid 3, 6, and 12 month plans for cash-paying patients [Ro, March 2026].
The bet
Ro's pitch is that a single membership can stitch together the prescriber visit, the labs, the medication, and the coaching that GLP-1 therapy requires. Ro Body, the company's weight loss program, is priced at $39 for the first month and as low as $74 per month on an annual prepay [Ro]. The program bundles GLP-1 medications, lab testing, and one-to-one coaching with provider care [PR Newswire]. Ro also offers Eli Lilly's Foundayo through the same channel [PR Newswire].
Weight loss is now the commercial center of gravity. Ro generated roughly $370 million in GLP-1 revenue in 2024 according to Sacra [Sacra]. The company has continued to broaden the ED catalog with compounded products including Daily Rise gummies and Sparks [Wikipedia], and it operates nationwide telehealth, labs, and pharmacy services [Built In NYC].
Why it could be big
The investor syndicate behind Ro reads like a bet that direct-to-patient care becomes a standalone channel. General Catalyst led a $500 million Series D in March 2021 [Ro, March 2021], following a $200 million Series C in July 2020 [Ro, July 2020]. ShawSpring led a further $150 million round in February 2022 [Tracxn]. Total disclosed funding sits near $1.03 billion.
| Metric | Value |
|---|---|
| Series C Jul 2020 | $200M |
| Series D Mar 2021 | $500M |
| Series D Feb 2022 | $150M |
| GLP-1 revenue 2024 | $370M |
The macro tailwind is the GLP-1 category itself. Ro's published outcomes data claims average weight loss of 11 to 20 percent at one year, compared with roughly 2 to 3 percent on diet and exercise alone [Ro].
The team and traction
Ro was co-founded by Zachariah Reitano, Rob Schutz, and Saman Rahmanian, with Reitano serving as chief executive [Initialized Capital]. Margo Georgiadis, formerly chief executive of Ancestry.com, joined the board of directors [Wikipedia]. Active hiring, including a Staff Software Engineer for Identity and Privacy and a Manager for Training and Quality Assurance in Customer Experience [Ro], suggests continued investment in the compliance and service layers.
The honest counterfactual
The most credible bear case is competitive and regulatory. Hims and Hers has built a public-market business on a similar DTC playbook. On the regulatory side, FDA scrutiny of compounded GLP-1s has tightened as the official shortage status has shifted. Ro's answer, visible in the Wegovy savings collaboration with Novo Nordisk [Ro, March 2026] and the inclusion of Lilly's Foundayo [PR Newswire], is to move the business toward branded, on-label dispensing with manufacturer-supported pricing.
What to watch
Over the next twelve months, the questions worth tracking are concrete. Does the Novo Nordisk savings program convert into measurable membership growth, and does Ro publish 68-week real-world outcomes that hold up to peer review [Ro]? Does the company expand the manufacturer collaboration model to additional branded therapies? And does Ro raise again, or begin signaling a path to public markets?